Holen Sie sich die Stockscreener-App
26.23
4.18%
-1.145
Handel nachbörslich:
26.39
0.16
+0.61%
Novocure Ltd Aktie (NVCR) Neueste Nachrichten
NovoCure Ltd (NVCR) Shares Down 3.67% on Jan 14 - GuruFocus.com
NovoCure (NASDAQ:NVCR) Earns "Buy" Rating from HC Wainwright - MarketBeat
Deep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings) - Benzinga
NovoCure’s (NVCR) Neutral Rating Reaffirmed at Wedbush - Defense World
NovoCure's (NVCR) Neutral Rating Reiterated at Wedbush - MarketBeat
Is Now The Time To Buy NovoCure Ltd (NASDAQ: NVCR) Stock? - Stocks Register
Novocure reports revenue growth, FDA approvals in 2024 - Investing.com India
Novocure Reports Strong 19% Revenue Growth, Hits $605M as Cancer Treatment Platform Expands - StockTitan
Investing in NovoCure (NASDAQ:NVCR) a year ago would have delivered you a 97% gain - Simply Wall St
NovoCure Limited (NASDAQ:NVCR) Shares Acquired by Versant Capital Management Inc - Defense World
NovoCure Limited (NASDAQ:NVCR) Receives $32.67 Average PT from Brokerages - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Novocure CEO to Present at J.P. Morgan Healthcare Conference, Announces Investor Meetings - StockTitan
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
NovoCure Limited (NASDAQ:NVCR) Shares Acquired by Franklin Resources Inc. - MarketBeat
Geode Capital Management LLC Acquires 29,871 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure (NASDAQ:NVCR) Reaches New 12-Month HighShould You Buy? - MarketBeat
Research Analysts’ Recent Ratings Updates for NovoCure (NVCR) - Defense World
Tumor Treating Fields Market Growth in Future Scope 2024-2031 | Novocure GmbH and Zai Lab - openPR
Novocure's SWOT analysis: oncology med-tech firm's stock faces growth challenges By Investing.com - Investing.com South Africa
Novocure's SWOT analysis: oncology med-tech firm's stock faces growth challenges - Investing.com
NovoCure (NASDAQ:NVCR) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Novocure Stock Hits 52-Week High at $32.65 Amidst Strong Yearly Growth - Investing.com Australia
NovoCure (NASDAQ:NVCR) Shares Gap Up on Analyst Upgrade - MarketBeat
Novocure price target raised to $42 from $28 at Piper Sandler - Yahoo Finance
Novocure Stock Hits 52-Week High at $32.65 Amidst Strong Yearly Growth By Investing.com - Investing.com South Africa
NovoCure (NASDAQ:NVCR) Price Target Raised to $42.00 - MarketBeat
Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction. - MSN
Brokerages Set NovoCure Limited (NASDAQ:NVCR) Target Price at $30.33 - MarketBeat
Quantinno Capital Management LP Cuts Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
47,034 Shares in NovoCure Limited (NASDAQ:NVCR) Bought by Weiss Asset Management LP - MarketBeat
NovoCure (NASDAQ:NVCR) Shares Gap UpHere's Why - MarketBeat
Holocene Advisors LP Purchases 22,276 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stake in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
MetLife Investment Management LLC Has $963,000 Holdings in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Why NovoCure Stock Was Winning Big This Week - Mitrade
BNP Paribas Financial Markets Has $2.75 Million Stock Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? - sharewise
CORRECTING and REPLACING – Novocure to Report Third Quarter 2016 Financial Results - Marketscreener.com
Edgestream Partners L.P. Takes Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Intech Investment Management LLC Makes New Investment in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
NovoCure Target of Unusually Large Options Trading (NASDAQ:NVCR) - Defense World
Novocure Stock Earns 96 RS Rating - Yahoo! Voices
NovoCure stock target increased on positive trial results By Investing.com - Investing.com Nigeria
NovoCure stock target increased on positive trial results - Investing.com
Novocure reports positive phase 3 results for tumor treating fields therapy - OutSourcing-Pharma.com
NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals - Yahoo Finance
Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint - Yahoo Finance
NovoCure Limited (NASDAQ:NVCR) Looks Just Right With A 84% Price Jump - Simply Wall St
Novocure stock hits 52-week high at $28.26 amid robust growth - Investing.com Canada
Bridgewater Associates LP Sells 41,898 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Evercore ISI Group Upgrades NovoCure (NVCR) - MSN
0.10%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):